RYTM EBITDA | RHYTHM PHARMACEUTICALS, INC.

RHYTHM PHARMACEUTICALS, INC. (RYTM) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$48.55M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$52.36M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$52.65M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$45.30M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2025-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$48.55M	(m)	$71.25M	(m)	(m)	-$9.15M*	$8.93M	$43.43M	$67.45M	$444.00K
2026-03-31	Reported	(m)	-$52.36M	(m)	$60.11M	(m)	(m)	-$44.19M	$7.16M	$41.73M	$63.59M	$545.00K
2025-09-30	Reported	(m)	-$52.65M	(m)	$51.30M	(m)	(m)	-$26.62M*	$5.50M	$46.03M	$52.42M	$111.00K
2025-06-30	Reported	(m)	-$45.30M	(m)	$48.50M	(m)	(m)	-$23.31M*	$5.54M	$42.31M	$45.95M	$337.00K
2025-03-31	Reported	(m)	-$47.00M	(m)	$32.70M	(m)	(m)	-$40.35M	$3.65M	$36.97M	$39.09M	$80.00K
2024-09-30	Reported	(m)	-$43.88M	(m)	$33.25M	(m)	(m)	-$25.21M*	$3.83M	$37.93M	$35.38M	-$344.00K
2024-06-30	Reported	(m)	-$40.48M	(m)	$29.08M	(m)	(m)	-$29.08M*	$2.95M	$30.19M	$36.41M	$479.00K
2024-03-31	Reported	(m)	-$139.89M	(m)	$25.97M	(m)	(m)	-$40.74M	$2.81M	$128.66M	$34.38M	$300.00K
2023-09-30	Reported	(m)	-$43.95M	(m)	$22.50M	(m)	$1.00K*	-$29.25M*	$2.41M	$33.57M	$30.48M	$368.00K
2023-06-30	Reported	(m)	-$46.60M	(m)	(m)	(m)	$0.00*	-$41.09M*	$2.24M	$33.54M	$30.05M	$0.00*
2023-03-31	Reported	(m)	-$52.53M	(m)	(m)	(m)	$47.00K	-$36.43M	$1.42M	$37.95M	$24.63M	$0.00
2022-09-30	Reported	(m)	-$39.27M	(m)	(m)	(m)	$95.00K*	-$46.99M*	$497.00K	$21.12M	$21.94M	(m)
2022-06-30	Reported	(m)	-$45.10M	(m)	(m)	(m)	$60.00K*	-$38.81M*	$378.00K	$31.46M	$22.33M	(m)
2022-03-31	Reported	(m)	-$52.69M	(m)	(m)	(m)	$127.00K	-$53.63M	$230.00K	$32.51M	$21.45M	$0.00
2021-12-31	Reported	-$51.01M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$43.92M*	-$44.24M	$315.00K*	(m)	(m)	$106.00K*	-$40.16M*	$222.00K	$27.54M	$17.51M	-$8.99M
2021-06-30	Reported	-$40.12M*	-$40.43M	$317.00K*	(m)	(m)	$248.00K*	-$31.84M*	$137.00K	$25.10M	$15.46M	-$5.02M
2021-03-31	Reported	-$34.2M	(m)	(m)	(m)	(m)	$12.00K	-$33.53M	$4.00K	$19.91M	$14.52M	$22.01M
2020-12-31	Reported	-$34.9M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$34.11M*	-$34.28M	$172.00K*	(m)	(m)	(m)	-$27.03M*	(m)	$23.00M	$11.29M	(m)
2020-06-30	Reported	-$31.75M*	-$31.92M	$173.00K*	(m)	(m)	(m)	-$29.73M*	(m)	$23.00M	$8.92M	(m)
2020-03-31	Reported	-$35.13M	(m)	(m)	(m)	(m)	(m)	-$36.10M	(m)	$22.50M	$12.80M	(m)
2019-12-31	Reported	-$34.03M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$36.92M*	-$37.11M	$191.00K*	(m)	(m)	$259.00K*	-$33.60M*	(m)	$26.57M	$10.54M	(m)
2019-06-30	Reported	-$43.94M*	-$44.15M	$207.00K*	(m)	(m)	$2.31M*	-$25.55M*	(m)	$35.31M	$8.84M	(m)
2019-03-31	Reported	-$30.28M	(m)	(m)	(m)	(m)	$811.00K	-$31.38M	(m)	$22.76M	$7.76M	(m)
2018-12-31	Reported	-$26.94M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$19.14M*	-$19.24M	$106.00K*	(m)	(m)	$317.00K*	-$16.94M*	(m)	$10.71M	$8.54M	(m)
2018-06-30	Reported	-$14.96M*	-$15.02M	$61.00K*	(m)	(m)	(m)	-$12.48M*	(m)	$8.58M	$6.44M	(m)
2018-03-31	Reported	-$16.94M	(m)	(m)	(m)	(m)	(m)	-$11.65M	(m)	$12.29M	$4.71M	(m)
2017-12-31	Reported	-$10.92M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$8.23M*	-$8.29M	$55.00K*	(m)	(m)	(m)	-$8.42M*	(m)	$5.97M	$2.31M	(m)
2017-06-30	Reported	-$6.70M*	-$6.75M	$54.00K*	(m)	(m)	(m)	-$6.14M*	(m)	$5.40M	$1.36M	(m)
2017-03-31	Reported	-$6.34M	(m)	(m)	(m)	(m)	(m)	-$7.02M	(m)	$4.87M	$1.52M	(m)
2016-12-31	Reported	-$8.32M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$6.40M	(m)	(m)	(m)	(m)	(m)	(m)	$5.42M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$191.52M	(m)	(m)	(m)	(m)	$953.00K	-$115.67M	$19.49M	$167.34M	$194.94M	$497.00K
2024-12-31	Reported	-$264.8M	(m)	(m)	(m)	(m)	$0.00	-$113.88M	$13.37M	$237.96M	$144.30M	$346.00K
2023-12-31	Reported	-$183.46M	(m)	(m)	(m)	(m)	$47.00K	-$136.16M	$9.30M	$134.95M	$117.53M	$564.00K
2022-12-31	Reported	-$178.26M	(m)	(m)	(m)	(m)	$281.00K	-$173.43M	$2.13M	$108.63M	$92.03M	(m)
2021-12-31	Reported	-$169.24M	(m)	(m)	(m)	(m)	$434.00K	-$146.00M	$599.00K	$104.13M	$68.49M	(m)
2020-12-31	Reported	-$135.89M	(m)	(m)	(m)	(m)	$214.00K	-$121.98M	(m)	$90.45M	$46.13M	(m)
2019-12-31	Reported	-$145.17M	(m)	(m)	(m)	(m)	$3.38M	-$122.75M	(m)	$109.45M	$36.55M	(m)
2018-12-31	Reported	-$77.98M	(m)	(m)	(m)	(m)	$722.00K	-$62.06M	(m)	$50.34M	$28.08M	(m)
2017-12-31	Reported	-$32.19M	(m)	(m)	(m)	(m)	$133.00K	-$29.46M	(m)	$22.89M	$9.52M	(m)
2016-12-31	Reported	-$25.76M	(m)	(m)	(m)	(m)	$1.06M	-$23.22M	(m)	$19.59M	$6.31M	(m)
2015-12-31	Reported	(m)	-$10.57M	(m)	(m)	(m)	$17.00K	-$6.75M	(m)	$7.15M	$3.42M	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Alkermes plc. (ALKS)		$6.844B	132.74
Liquidia Corp (LQDA)	United States	$6.347B	51.23
Amneal Pharmaceuticals, Inc. (AMRX)		$6.326B	25.62
IONIS PHARMACEUTICALS INC (IONS)	United States	$7.277B	-23.25
Spyre Therapeutics, Inc. (SYRE)	United States	$7.685B	-43.69
Structure Therapeutics Inc. (GPCR)	United States	$7.710B	-53.41
Mirum Pharmaceuticals, Inc. (MIRM)	United States	$5.798B	-8.81
Travere Therapeutics, Inc. (TVTX)	United States	$5.712B	-123.10
Oruka Therapeutics, Inc. (ORKA)	United States	$5.663B	-43.76
Praxis Precision Medicines, Inc. (PRAX)	United States	$7.884B	-27.60